Literature DB >> 10211564

Reduction of tumorigenicity by an interferon-gamma-gene-transduced tumor on another syngeneic tumor in a murine model.

Y Ichinose1, T Okino, S Yamasaki, Y Moriguchi, T Sugie, L Li, S Kanaoka, N Kan, Y Watanabe, M Imamura.   

Abstract

To evaluate the effect of interferon-gamma-gene-transduced cells, DS mice were inoculated into their footpads with syngeneic mammary adenocarcinoma SC42 admixed with interferon-gamma producing mammary adenocarcinoma SC115Kgamma, which had been established by an interferon-gamma-gene transduction in another syngeneic mammary adenocarcinoma SC115 using retroviral vectors. These mice rejected both tumor cells and developed resistance to subsequent challenges with either SC115 or SC42 cells inoculated into their opposite posterior footpads. These results thus indicate that systemic immunological memory to each of the independent tumor cell lines developed in these mice. Although the SC42 cells admixed with irradiated SC115Kgamma cells were rejected by these mice, the SC42 cells admixed with irradiated SC115neoR, in which the neo-gene had been transduced, were observed to proliferate. Tumor rejection was reversed by an in vivo administration of anti-interferon-gamma antibody, thus suggesting that locally produced interferon-gamma plays an important role in tumor elimination and immunological memory induction. In conclusion, interferon-gamma-gene-transduced tumor cells are therefore considered to have a therapeutic potential for other types of malignant tumor cell lines.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10211564     DOI: 10.1007/bf02483058

Source DB:  PubMed          Journal:  Surg Today        ISSN: 0941-1291            Impact factor:   2.549


  20 in total

1.  An androgen-dependent mouse mammary tumor.

Authors:  T Minesita; K Yamaguchi
Journal:  Cancer Res       Date:  1965-08       Impact factor: 12.701

2.  A Phase I clinical trial of immunotherapy with interferon-gamma gene-modified autologous melanoma cells: monitoring the humoral immune response.

Authors:  Z Abdel-Wahab; C Weltz; D Hester; N Pickett; C Vervaert; J R Barber; D Jolly; H F Seigler
Journal:  Cancer       Date:  1997-08-01       Impact factor: 6.860

3.  Exogenous expression of mouse interferon gamma cDNA in mouse neuroblastoma C1300 cells results in reduced tumorigenicity by augmented anti-tumor immunity.

Authors:  Y Watanabe; K Kuribayashi; S Miyatake; K Nishihara; E Nakayama; T Taniyama; T Sakata
Journal:  Proc Natl Acad Sci U S A       Date:  1989-12       Impact factor: 11.205

4.  Antitumor potential of interferon-gamma: retroviral expression of mouse interferon-gamma cDNA in two kinds of highly metastatic mouse tumor lines reduces their tumorigenicity.

Authors:  K Yanagihara; T Seyama; Y Watanabe
Journal:  Nat Immun       Date:  1994 Mar-Jun

5.  [Tumor-specific cytotoxicity of tumor infiltrating lymphocytes (TIL) induced with TCGF in murine mammary carcinoma].

Authors:  T Hori; N Kan; K Ohgaki; N Yamazaki; N Nakayama; Y Nio; T Inamoto
Journal:  Nihon Geka Gakkai Zasshi       Date:  1984-08

6.  IFN-gamma retards the turnover of H-2Dd antigens by splenic lymphocytes.

Authors:  A Guha; R E Cone
Journal:  J Immunol       Date:  1991-03-15       Impact factor: 5.422

Review 7.  The molecular cell biology of interferon-gamma and its receptor.

Authors:  M A Farrar; R D Schreiber
Journal:  Annu Rev Immunol       Date:  1993       Impact factor: 28.527

8.  Highly efficient action of autocrine mouse interferon-gamma expressed via a retroviral vector.

Authors:  Y Watanabe; T Sakata
Journal:  Eur J Immunol       Date:  1988-10       Impact factor: 5.532

9.  Intraperitoneal recombinant interferon gamma in ovarian cancer patients with residual disease at second-look laparotomy.

Authors:  E Pujade-Lauraine; J P Guastalla; N Colombo; P Devillier; E François; P Fumoleau; A Monnier; M Nooy; L Mignot; R Bugat; C Marques; M Mousseau; G Netter; F Maloisel; S Larbaoui; M Brandely
Journal:  J Clin Oncol       Date:  1996-02       Impact factor: 44.544

10.  Interferon-gamma-producing tumor induces host tumor-specific T cell responses.

Authors:  Y Teramura; Y Watanabe; N Kan; T Masuda; K Kuribayashi
Journal:  Jpn J Cancer Res       Date:  1993-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.